Five promising approaches to expand the depression armory
This article was originally published in Scrip
The paucity of candidates in the pipeline for the treatment of depression has been causing concern for some time. However, recent Datamonitor Healthcare analysis has identified five approaches to treating depression, all still at a relatively early stage of investigation, that could revitalize the field in coming years:
You may also be interested in...
Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.